Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis

European Journal of Heart Failure

Volumn 14, Issue 7, 2012, Pages 681-695

  Lip, Gregory Y H ^a   Ponikowski, Piotr ^b   Andreotti, Felicita ^c   Anker, Stefan D ^d   Filippatos, Gerasimos ^e   Homma, Shunichi ^f   Morais, Joao ^g   Pullicino, Patrick ^h,i   Rasmussen, Lars H ^j   Marin, Francisco ^k   Lane, Deirdre A ^a   McMurray, John ^l   Hoes, Arno ^l   Ten Berg, Jurrien ^l   De Caterina, Raffaele ^l   Kristensen, Steen ^l   Zeymer, Uwe ^l  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c CATHOLIC UNIVERSITY   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^f NewYork Presbyterian Hospital   (United States)

^g Cardiology Division   (Portugal)

^h UNIVERSITY OF KENT   (United Kingdom)

ⁱ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^j AALBORG UNIVERSITY HOSPITAL   (Denmark)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^l NONE

more..

Author keywords

Antithrombotic therapy; Aspirin; Heart failure; Sinus rhythm; Thrombo embolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC IMAGING; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; DATA ANALYSIS; DEFIBRILLATOR; DIAGNOSTIC IMAGING; DRUG ANTAGONISM; DRUG WITHDRAWAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PATIENT PREFERENCE; POST HOC ANALYSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SINUS RHYTHM; SOCIAL PSYCHOLOGY; STENT THROMBOSIS; STROKE; THROMBOEMBOLISM;

ASPIRIN; CONFIDENCE INTERVALS; EUROPE; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK FACTORS; THROMBOEMBOLISM; WARFARIN;

EID: 84862848177     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs073     Document Type: Review

References (120)

1. Witt BJ, Gami AS, Ballman KV, Brown RD Jr, Meverden RA, Jacobsen SJ, Roger VL. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007;13:489-496. (Pubitemid 47176922)
2. Alberts VP, Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Stricker BH, Breteler MM. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010;25:807-812.
3. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, Roger VL. Ischemic stroke after heart failure: a community-based study. Am Heart J 2006;152:102-109. (Pubitemid 43974732)
4. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000;102:611-616. (Pubitemid 30640659)
5. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129.
6. Piazza G, Goldhaber SZ, Lessard DM, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in heart failure: preventable deaths during and after hospitalization. Am J Med 2011;124:252-259.
7. Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies. Thromb Haemost 2011; 106:600-608.
8. Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medicine. Frankfurt: Meidinger Sohn & Co; 1856. pp.219-732.
9. Freudenberger RS, Schumaecker MM, Homma S. What is the appropriate approach to prevention of thromboembolism in heart failure? Thromb Haemost 2010;103:489-695.
10. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999;33:1424-1426.
11. Fisher D, Rossa S, Landmesser U, Spikermann S, Engberding N, Hornig B, Drexler H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cadiac transplantation, or death. Eur Heart J 2005;26:65-69. (Pubitemid 40221125)
12. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001;103:1746-1751. (Pubitemid 32291411)
13. Chong AY, Freestone B, Patel, Lim H, Hughes E, Blann AD, Lip GYH. Endothelial activation, dysfunction and damage in chronic heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006;97:671-675. (Pubitemid 43255037)
14. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GYH. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004;110:1794-1798. (Pubitemid 39302656)
15. Kapur NK, Deming CB, Kapur S, Bian C, Champion HC, Donahue JK, Kass DA, Rade JJ. Hemodynamic modulation of endocardial thromboresistance. Circulation 2007;115:67-75. (Pubitemid 46058613)
16. Alehagen U, Dahlstrom U, Lindahl TL. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004;92:1250-1258. (Pubitemid 39642533)
17. Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011;106:457-465.
18. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-612. (Pubitemid 24124691)
19. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-1878.
20. Besarab A, Hö rl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 2009;14 Suppl 1: 22-33.
21. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke-predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003;34:122-126. (Pubitemid 36070812)
22. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, Homma S, Di Tullio MR. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006;37:1715-1719. (Pubitemid 44297718)
23. Grigorian-Shamagian L, Otero Raviña F, Abu Assi E, Vidal Perez R, Teijeira-Fernandez E, Varela Roman A, Moreira Sayagues L, Gonzalez-Juanatey JR. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of .600 deaths in a community long-term study. Am Heart J 2008;156:1184-1190.
24. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208-216.
25. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan stroke study. Neurology 1994;44:626-634. (Pubitemid 24129987)
26. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham Study. JAMA 1983;250:2942-2946. (Pubitemid 14202371)
27. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006;98: 793-795. (Pubitemid 44301013)
28. Darze ES, Latado AL, Guimaraes AG, Guedes RA, Santos AB, de Moura SS, Passos LC. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest 2007;131: 1838-1843. (Pubitemid 46981643)
29. Falk RH, Foster E, Coats MH. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective follow-up study. Am Heart J 1992;123: 136-142.
30. Blondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am Heart J 1991;122:763-771.
31. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenbury RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-531. (Pubitemid 11137647)
32. Gottdiener JS, Gay JA, VanVoorhees L, DiBianco R, Fletcher RD. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am J Cardiol 1983;52:1281-1285. (Pubitemid 14243987)
33. Ciaccheri M, Castelli G, Cecchi F, Nannini M, Santoro G, Troiani V, Zuppiroli A, Dolara A. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 1989;62:26-29. (Pubitemid 19171232)
34. Sharma S, McCullough PA, Philbin EF, Weaver WD. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest 2000;117:314-320. (Pubitemid 30111577)
35. Diaz RA, Obasohan A, Oakley CM. Prediction of outcome in dilated cardiomyopathy. Br Heart J 1987;58:393-399. (Pubitemid 17152520)
36. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995;129:564-570.
37. Katz SD, Marantz PR, Biasucci L, Jondeau G, Lee K, Brennan C, LeJemtel TH. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993;126:141-146. (Pubitemid 23201585)
38. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, Tavazzi L. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996;17:1381-1389. (Pubitemid 26306667)
39. Chung I, Lip GYH. Antithrombotic therapy for chronic heart failure. Int J Clin Pract 2006;60:36-47. (Pubitemid 43732575)
40. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe chronic heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
41. Dunkman WB, Johnson GR, Carson PE, Bhag G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 Suppl):VI94-V101.
42. Freudenberger RS, Hellkamp A, Halperin JL, Poole J, Anderson J, Johnson G, Mark DB, Lee KL, Brady GH, SCD-HeFT Investigators. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007;115:2637-2641. (Pubitemid 46791362)
43. Loh E, Suton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moyé LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257. (Pubitemid 27044626)
44. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080. (Pubitemid 27149584)
45. Erratum in J Am Coll Cardiol 1998;32:555.
46. Falk RH, Pollak A, Tandon PK, Parker M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J Am Coll Cardiol 1993;21:218 (Abstract).
47. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-753. (Pubitemid 28186406)
48. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-425. (Pubitemid 28153463)
49. Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD; VALIANT Trial Investigators. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J 2007;28: 685-691. (Pubitemid 46439219)
50. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
51. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. (Pubitemid 350190755)
52. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
53. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180-2183. (Pubitemid 39372498)
54. StevensonWG, Stevenson LW, Midlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993;33:1424-1426.
55. Anderson GM, Hull E. The effects of dicumarol upon the mortality and incidence of thromboembolic complication in congestive heart failure. Am Heart J 1950;39: 697-702.
56. Harvey WP, Finch CA. Dicoumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950;242:208-211.
57. Griffith GC, Stragnell R, Levinson DC, Moore FJ,Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952;37:867-887.
58. Cleland JGF, Findlay I, Jafri S, Sutton G, Galk R, Bulpitt C, Prentice C, Ford I, Trainer A, Poole-Wilson PA. The warfarin/aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-164. (Pubitemid 38900496)
59. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutozas PK for the HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;8:428-432. (Pubitemid 43832171)
60. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M, Jafri SM, Krol WF, O'Connor C, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616-1624.
61. Pullicino P, Thompson JL, Barton B, Levin B, Graham S, Freudenberger RS; WARCEF Investigators.Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006;12:39-46. (Pubitemid 43267750)
62. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, Del Valle ML, Buchsbaum R; the WARCEF Investigators. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. N Engl J Med 2012 [Epub ahead of print] doi:10.1056/NEJMoa1202299.
63. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
64. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
65. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, TangWH, Teerlink JR,Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:e1-e194.
66. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 2007;38:2935-2940. (Pubitemid 350035686)
67. Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen MS, Rohani P, Halperin JL; IMPACT Investigators. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009;158:364-370.e1.
68. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Mar?́n F, Palareti G, Kirchhof P; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011;106:997-1011.
69. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100.
70. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010;104:1099-1105.
71. Mant J, Hobbs R, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA). A randomised controlled trial. Lancet 2007;370:493-503. (Pubitemid 47212371)
72. Warkentin AE, Donadini MP, Spencer FA, Lim W, Crowther M. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. J Thromb Haemost 2012;10:512-520.
73. Mansencal N, Revault-d'Allonnes L, Pelage JP, Farcot JC, Lacombe P, Dubourg O. Usefulness of contrast echocardiography for assessment of intracardiac masses. Arch Cardiovasc Dis 2009;102:177-183.
74. Sen S, Laowatana S, Lima J, Oppenheimer SM. Risk factors for intracardiac thrombus in patients with recent ischaemic cerebrovascular events. J Neurol Neurosurg Psychiatry 2004;75:1421-1425. (Pubitemid 39279810)
75. Kapral MK, Silver FL. Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. CMAJ 1999;161:989-996.
76. Lee RJ, Bartzokis T, Yeoh TK, Grogin HR, Choi D, Schnittger I. Enhanced detection of intracardiac sources of cerebral emboli by transesophageal echocardiography. Stroke 1999;22:734-739.
77. Mollet NR, Dymarkowski S, Volders W, Wathiong J, Herbots L, Rademakers FE, Bogaert J. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 2002;106: 2873-2876. (Pubitemid 35424733)
78. Bleiweis MS, Georgiou D, Brundage BH. Detection of intracardiac masses by ultrafast computed tomography. Am J Card Imag 1994;8:63-68. (Pubitemid 24057565)
79. Riegel B, Carlson B, Moser DK, Sebern M, Hicks FD, Roland V. Psychometric testing of the self-care of heart failure index. J Card Fail 2004;10:350-360. (Pubitemid 39092689)
80. Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, Gurvitz MZ, Havranek EP, Lee CS, Lindenfield J, Peterson PN, Pressler SJ, Schocken DD, Whellan DJ. State of the Science: Promoting self-care in persons with heart failure: a Scientific Statement from the American Heart Association. Circulation 2009;120:1141-1163.
81. Mart?́nez-Sellés M, Garc?́a Robles JA, Muñoz R, Serrano JA, Frades E, Dom?́nguez Muñoa M, Almendral J. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail 2004;6:219-226. (Pubitemid 38249366)
82. Zick SM, Blume A, Aaronson KD. The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail 2005;11:586-589. (Pubitemid 41463728)
83. Granger BB, Ekman I, Granger CB, Ostergren J, Olofsson B, Michelson E, McMurray JJ, Yusuf S, Pfeffer MA, Swedberg K. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail 2009;11: 1092-1098.
84. Morrow DG, Weiner M, Steinley D, Young J, Murray MD. Patients' health literacy and experience with instructions influence preferences for heart failure medication instructions. J Aging Health 2007;19:575-593. (Pubitemid 47062975)
85. Morrow DG, Weiner M, Deer MM, Young JM, Dunn S, McGuire P, Murray MD. Patient-centered instructions for medications prescribed for the treatment of heart failure. Am J Geriatr Pharmacother 2004;2:44-52. (Pubitemid 38559458)
86. Schreurs KM, Colland VT, Kuijer RG, de Ridder DT, van Elderen T. Development, content, and process evaluation of a short self-management intervention in patients with chronic diseases requiring self-care behaviours. Patient Educ Couns 2003;51:133-141. (Pubitemid 37311330)
87. Shively M, Kodiath M, Smith TL, Kelly A, Bone P, Fetterly L, Gardetto N, Shabetai R, Bozzette S, Dracup K. Effect of behavioral management on quality of life in mild heart failure: a randomized controlled trial. Patient Educ Couns 2005;58:27-34. (Pubitemid 40799161)
88. Lane DA, Chong AY, Lip GYH. Psychological interventions for depression in heart failure. Cochrane Database Syst Rev 2005;(1):CD003329.
89. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527-1537. (Pubitemid 44528168)
90. Sullivan M, Simon G, Spertus J, Russo J. Depression-related costs in heart failure care. Arch Intern Med 2002;162:1860-1866.
91. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG, Hinderliter AL. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007;167:367-373. (Pubitemid 46333937)
92. Heo S, Moser DK, Lennie TA, Zarnbroski CH, Chung ML. A comparison of health-related quality of life between older adults with heart failure and healthy older adults. Heart Lung 2007;36:16-24. (Pubitemid 46096594)
93. Lip GYH, Chung I. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2000;(4):CD003333.
94. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-272.
95. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH; ESC Committee for Practice Guidelines, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P; Document Reviewers, Vardas PE, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlö f B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
96. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e637S-68S.
97. Lip GYH, Chung I. Anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2000;(4):pCD003336.
98. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Windecker S, Achenbach S, Badimon L, Bertrand M, Bøtker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
99. Lip GYH, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Mar?́n F European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting: a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010;103:13-28.
100. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011;106:572-584.
101. Huber K, Airaksinen KJ, Cuisset T, Mar?́n F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011;106:569-571.
102. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-1974.
103. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society of Heart Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-956.
104. Ensor CR, Paciullo CA, Cahoon WD Jr, Nolan PE Jr. Pharmacotherapy for mechanical circulatory support: a comprehensive review. Ann Pharmacother 2011;45: 60-77.
105. Lazar RM, Shapiro PA, Jaski BE, Parides MK, Bourge RC, Watson JT, Damme L, DembitskyW, Hosenpud JD, Gupta L, Tierney A, Kraus T, Naka Y. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistatnce for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 2004;109:2423-2427. (Pubitemid 38679562)
106. Ensor CR, Cahoon WD, Crouch MA, Katlaps GJ, Hess ML, Cooke RH, Gunnerson KJ, Kasirajan V. Antithrombotic therapy for the CardioWest temporary total artificial heart. Texas Heart Inst J 2010;37:149-158.
107. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867. (Pubitemid 351650486)
108. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; ACCF/AHA/HRS. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:223-242.
109. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104:49-60.
110. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14-21.
111. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631-639. (Pubitemid 35176095)
112. Pullicino PM, McClure LA, Howard VJ, Wadley VG, Safford MM, Meschia JF, Anderson A, Howard G, Soliman EZ. Identifying a high stroke risk subgroup in individuals with heart failure. J Stroke Cerebrovasc Dis 2011 (Published online 6.12.2011) http://www.strokejournal.org/article/S1052-3057(11)00295-3/abstract.
113. Pullicino P, Homma S, Thompson JL, Freudenberger RS, Sacco RL, Mohr JP. Oral anticoagulation in patients with cardiomyopathy or heart failure in sinus rhythm. Cerebrovasc Dis 2008;26:322-327.
114. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012;14: 295-301.
115. Banerjee A, Mar?́n F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke 2011;42:3316-3322.
116. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
117. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
118. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
119. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-1115.
120. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-1127.